Table 4.
Validity of the clusters for system summary (SS) and baseline (BL)
| Topic |
Cohesion |
Separation |
Overall Validity |
|||
|---|---|---|---|---|---|---|
| SS | BL | SS | BL | SS | BL | |
| Diabetes Mellitus |
0.38 |
0.41 |
0.70 |
0.22 |
0.46 |
0.29 |
| (95% CI) |
(0.32-0.45) |
(0.35-0.48) |
(0.64-0.76) |
(0.17-0.28) |
(0.43-0.56) |
(0.23-0.35) |
| Lung Neoplasms |
0.46 |
0.51 |
0.51 |
0.22 |
0.48 |
0.31 |
| (95% CI) |
(0.34-0.57) |
(0.40-0.62) |
(0.39-0.63) |
(0.13-0.31) |
(0.36-0.60) |
(0.20-0.40) |
| Schizophrenia |
0.81 |
0.86 |
0.91 |
0.35 |
0.86 |
0.50 |
| (95% CI) |
(0.70-0.92) |
(0.76-0.96) |
(0.84-0.99) |
(0.22-0.48) |
(0.76-0.96) |
(0.36-0.64) |
| Hypersensitivity |
0.46 |
0.54 |
0.38 |
0.23 |
0.42 |
0.32 |
| (95% CI) |
(0.37-0.54) |
(0.46-0.63) |
(0.30-0.46) |
(0.16-0.30) |
(0.33-0.50) |
(0.24-0.40) |
| Oxidative stress |
0.39 |
0.52 |
0.35 |
0.18 |
0.37 |
0.27 |
| (95% CI) |
(0.32-0.46) |
(0.45-0.58) |
(0.28-0.41) |
(0.13-0.23) |
(0.30-0.43) |
(0.21-0.32) |
| Hydrocortisone |
0.54 |
0.54 |
0.59 |
0.59 |
0.56 |
0.56 |
| (95% CI) |
(0.47-0.62) |
(0.50-0.58) |
(0.51-0.66) |
(0.55-0.63) |
(0.49-0.64) |
(0.52-0.60) |
| Heat-Shock Proteins |
0.54 |
0.54 |
0.24 |
0.16 |
0.33 |
0.25 |
| (95% CI) |
(0.47-0.60) |
(0.47-0.60) |
(0.19-0.30) |
(0.11-0.20) |
(0.27-0.40) |
(0.19-0.29) |
| Anti-inflammatory Agents, Non-steroidal |
0.49 |
0.48 |
0.71 |
0.43 |
0.58 |
0.45 |
| (95% CI) |
(0.42-0.56) |
(0.41-0.55) |
(0.64-0.77) |
(0.37-0.50) |
(0.51-0.65) |
(0.38-0.52) |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors |
0.38 |
0.43 |
0.35 |
0.24 |
0.36 |
0.31 |
| (95% CI) |
(0.31-0.45) |
(0.36-0.50) |
(0.28-0.42) |
(0.18-0.29) |
(0.29-0.43) |
(0.24-0.37) |
| Tumor Necrosis Factors |
0.53 |
0.51 |
0.31 |
0.54 |
0.39 |
0.52 |
| (95% CI) |
(0.45-0.61) |
(0.42-0.60) |
(0.23-0.38) |
(0.46-0.63) |
(0.31-0.47) |
(0.44-0.61) |
| Overall |
0.47 |
0.51 |
0.40 |
0.24 |
0.43 |
0.33 |
| (95% CI) | (0.45-0.50) | (0.49-0.54) | (0.38-0.42) | (0.22-0.26) | (0.41-0.46) | (0.31-0.35) |